Scholar Rock Holding Corporation announced that it has resubmitted its Biologics License Application (BLA) for apitegromab, its lead spinal muscular atrophy (SMA) therapy, to the U.S. Food and Drug Administration (FDA) on March 31 2026. The resubmission follows a Complete Response Letter issued in September 2025 that cited manufacturing compliance issues at the company’s third‑party fill‑finish partner, Catalent Indiana, now part of Novo Nordisk.
To address the FDA’s concerns, Scholar Rock has engaged a second U.S.‑based fill‑finish partner and incorporated corrective actions recommended by the agency. A Type C meeting held on March 3 2026 confirmed the company’s plan to meet all regulatory requirements. The company now expects a PDUFA action date in late September 2026, which would allow apitegromab to enter the U.S. market in 2026 after FDA review.
Financially, Scholar Rock reported a net loss of $91.0 million for Q4 2025 and $377.9 million for the full year, compared with $66.5 million and $246.3 million in the prior year. The company’s cash, cash equivalents, and marketable securities stood at $367.6 million as of December 31 2025, and it has secured a new debt facility of up to $550 million with Blue Owl Capital to support ongoing development and potential commercialization.
The SMA market is projected to grow from $4.40 billion in 2024 to $13.09 billion by 2030, with a CAGR of 18.0%. Apitegromab’s muscle‑targeted mechanism could complement existing gene therapies and SMN‑targeted drugs such as Zolgensma, Spinraza, and Evrysdi, potentially addressing unmet needs in patients already receiving SMN‑directed treatments.
CEO David L. Hallal said, "Our apitegromab BLA resubmission marks an important step forward in our mission to bring the world's first muscle‑targeted therapy to children and adults living with SMA. We continue to be encouraged by the FDA's engagement and shared sense of urgency as we work relentlessly for the SMA community." He added, "Scholar Rock is at an inflection point as we evolve to a commercial‑stage biopharmaceutical company, and our team remains focused on key priorities in preparation for the potential U.S. launch of apitegromab in Q3 2025." CFO Vikas Sinha noted, "We continue to strengthen our balance sheet and are pleased to announce today that we secured a new debt facility for up to $550 million with Blue Owl Capital."
Investors have responded positively to the announcement, citing Scholar Rock's strengthened financial position and progress on the regulatory path. The company’s ability to secure additional debt and maintain a robust cash reserve, combined with the FDA’s acceptance of the corrective plan, signals confidence in the company’s ability to navigate the remaining regulatory hurdles and move apitegromab toward market entry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.